Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Buoyant market for magnetic resonance imaging (MRI) contrast media in Japan:

This article was originally published in Clinica

Executive Summary

The Japanese market for MRI contrast media is worth around ¥0,000 million ($91 million) at official reimbursement prices, estimates Japan Medical Review. This is forecast to rise to Yen17,000 million by 1998, reflecting the expected growth of MRI scanning and increase in the number of scanners in Japan. Daiichi, which recently launched Nycomed's MRI contrast agent, Omniscan, in Japan (see Clinica No 713, p 9), estimates Omniscan sales will total Yen1,500 million in its first year on the market, rising to Yen4,000 million by 1998.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT088719

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel